Ritesh Kumar

Dr. Ritesh Kumar

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2012 in Acta Neurochirurgica
Verified
Journal Article
Closed access
PDF file
NKNarendra Kumar
Narendra Kumar
RKRitesh Kumar
Ritesh Kumar
RKRAKESH KAPOOR
RAKESH KAPOOR
SGSushmita Ghoshal
Sushmita Ghoshal
PKPramod Kumar
Pramod Kumar
SSSuresh Chander Sharma
Suresh Chander Sharma

1 January 2015 in World Journal of Clinical Cases
Verified
Journal Article
Open access
RKRitesh Kumar
Ritesh Kumar
Esthesioneuroblastoma (ENB) is a rare malignant neoplasm arising from the olfactory neuroepithelium. ENB constitutes only 3% of all malignant intranasal neoplasm. Because of the rarity, the number of patients of ENB treated in individual departments is small. Most of these patients presents in locally advanced stages and require multimodality treatment in form of surgery, chemotherapy and radiotherapy. Multimodality approach with a risk-adapted strategy is required to achieve good control rates while minimizing treatment related toxicity.

1 January 2015 in World Journal of Clinical Cases
Verified
Journal Article
Open access
RKRitesh Kumar
Ritesh Kumar
Thymoma is the most common mediastinal tumor. They have varied presentation ranging from asymptomatic incidental mediastinal masses to locally extensive tumor with compressive symptoms and distant metastases. They have frequent association with various paraneoplastic syndromes (PNS). The most common PNS associated with thymoma is myasthenia gravis (MG). Patients of thymoma with MG have a favourable outcome due to early disclosure of the disease. Histologically they are classified into five subtypes and Masaoka-Koga staging system is used for staging. Surgery, chemotherapy and radiotherapy play an important role along with anti-myasthenia drugs. This review would like to highlight the association of thymoma with MG and associated clinical and therapeutic issues.

15 October 2014 in Journal of Gastrointestinal Cancer
Verified
Journal Article
Closed access
PDF file
LDL Purnima Devi
L Purnima Devi
RKRitesh Kumar
Ritesh Kumar
AHAkash Handique
Akash Handique
MKMahendra Kumar
Mahendra Kumar

1 April 2013 in Indian Journal of Urology
Verified
Journal Article
Open access
PDF file
RKRitesh Kumar
Ritesh Kumar
RKRakesh Kapoor
Rakesh Kapoor
DKDivya Khosla
Divya Khosla
NKNarendra Kumar
Narendra Kumar
SGSushmita Ghoshal
Sushmita Ghoshal
SSSuresh Chander Sharma
Suresh Chander Sharma
Introduction: Paratesticular rhabdomyosarcoma (RMS) is a rare tumor arising from the mesenchymal tissues of the spermatic cord, epididymis, testis and testicular tunics. It represents only 7% of all patients entered in the Intergroup Rhabdomyosarcoma Study (IRS) and 17% of all malignant intrascrotal tumors in children less than 15 years old. We present our experience in combined modality management of 10 successive patients of paratesticular RMS. Material and Methods: We retrospectively reviewed 10 patients of paratesticular RMS treated in our institute from July 2004 to December 2010. Clinical characteristics and treatment modality in form of surgery and chemotherapy (CCT) were noted. Statistical analysis was done with regards to progression-free survival (PFS) and overall survival (OS) using Kaplan-Meier survival analysis. Results: The median age of the patients was 16.5 years. The median duration of symptoms was 5 months. Five patients had retroperitoneal lymphadenopathy (RPLAP) while three had lung metastases and one had orbital metastases. All patients underwent high inguinal orchidectomy followed by systemic chemotherapy (CCT). Retroperitoneal node dissection was not a required staging procedure. Four patients had partial response to treatment while six had complete response. Mean duration of PFS was 48 months and mean OS was 56 months. Conclusions: Paratesticular RMS are rare neoplasms with aggressive growth patterns. Cure rates have dramatically improved and 60% of patients in our series had complete response. This success is due to development of multimodality and risk adapted treatment approaches.

21 November 2012 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Closed access
PDF file
RKRitesh Kumar
Ritesh Kumar
SGSushmita Ghoshal
Sushmita Ghoshal
DKDivya Khosla
Divya Khosla
SBShreekant Bharti
Shreekant Bharti
ADAshim Das
Ashim Das
SSSuresh Chander Sharma
Suresh Chander Sharma